Grail is set to start a new trial next year to assess the ability of an investigational blood test to detect a number of cancer types.

SUMMIT is a prospective observational, longitudinal, cohort study that aims to enrol around 50,000 men and women aged 50 to 77 years who do not have a cancer diagnosis at the time of recruitment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Nearly half of participants will be at high risk of developing lung and other cancers because of their significant smoking history.

Healthcare company Grail is expected to use next-generation sequencing (NGS) technology as part of the trial.

“SUMMIT will support the development of our blood test for the early detection of multiple cancer types in a diverse population.”

It plans to carry out the trial in the UK in collaboration with University College London (UCL) and the university’s National Health Service (NHS) Foundation Trust (UCLH).

US-based non-profit organisation Lung Cancer Alliance (LCA) will provide guidance on the study design of SUMMIT.

Grail Clinical Development vice-president Anne-Renee Hartman said: “The SUMMIT study will support the development of our blood test for the early detection of multiple cancer types in a diverse population.”

SUMMIT aims to help UCL and UCLH achieve their goal of evaluating the feasibility of implementing lung cancer screening in the UK.

Participants are also expected to have the opportunity to undergo lung cancer screening with low dose computed tomography (LDCT) and will have support for smoking cessation through the NHS in the UK.

LDCT is recommended by the US Preventive Services Task Force (USPSTF) for use in people who are at high risk for lung cancer due to current or former smoking habit.